Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482976 | 0.84 | GAA (0.35) | GAAADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL2204312 | 0.81 | ADRA2A (0.47) | GAAADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL11891102 | 0.78 | SMN1; SMN2 (0.42) | KCNH2IDO1TDO2CYP11B1CYP11B2 | |
| SCHEMBL13089076 | 0.78 | KCNN4 (0.35) | ADRA2AADRA2BADRA2CADRA1DTSHR | |
| SCHEMBL3026300 | 0.77 | TSHR (0.34) | GAAADRA1ATSHRTP53CYP3A4 | |
| SCHEMBL11891091 | 0.76 | CYP11B1 (0.39) | ADRA2AADRA2BADRA2CADRA1DTSHR | |
| SCHEMBL3143338 | 0.74 | HSP90AA1 (0.44) | GAACYP3A4CYP2D6CYP2C19IDO1 | |
| SCHEMBL1482980 | 0.74 | SMN1; SMN2 (0.39) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8052945 | 0.74 | GAA (0.38) | GAAADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL12510466 | 0.73 | SIRT2 (0.35) | GAACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2250153-B1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2079706-B1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | GRINDEKS JSC (LV) | 2011-07-20 | — | — | EP | disclosed |
| EP-2240453-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100048915-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS. | GRINDEKS A JOINT STOCK COMPANY (LV) | 2010-02-25 | — | — | US | disclosed |
| WO-2009091735-A1 | SUBSTITUED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN.INC (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-2079706-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | Grindeks, a joint stock company (LV) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009089132-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089132-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| WO-2008055852-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2008-05-15 | — | — | WO | disclosed |
| EP-1918282-A1 | Method for preparing medetomidine and its salts | "Joint Stock Company Grindeks" (LV) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048915-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS. | ADRB2, ADRB3, OPRM1 | GAA 3738/4885ADRA2A 15/4885ADRA2B 6/4885 |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB2, ADRB3 | GAA 4126/4885ADRA2A 7/4885ADRA2B 4/4885 |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB3, ADRB2 | GAA 3693/4885ADRA2A 8/4885ADRA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.